U.S. Markets closed
  • S&P Futures

    3,656.50
    +33.25 (+0.92%)
     
  • Dow Futures

    29,888.00
    +259.00 (+0.87%)
     
  • Nasdaq Futures

    12,389.00
    +112.00 (+0.91%)
     
  • Russell 2000 Futures

    1,843.30
    +23.20 (+1.27%)
     
  • Crude Oil

    44.99
    -0.35 (-0.77%)
     
  • Gold

    1,788.90
    +8.00 (+0.45%)
     
  • Silver

    22.98
    +0.39 (+1.71%)
     
  • EUR/USD

    1.1962
    +0.0027 (+0.2273%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3359
    +0.0028 (+0.2084%)
     
  • USD/JPY

    104.4330
    +0.1090 (+0.1045%)
     
  • BTC-USD

    19,548.45
    +38.57 (+0.20%)
     
  • CMC Crypto 200

    383.69
    +19.09 (+5.24%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

GLNG, GTX & BMRN Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Upcoming Lead Plaintiff Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / October 21, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Golar LNG Limited (NASDAQ:GLNG)
Class Period: April 30, 2020 - September 24, 2020
Deadline: November 23, 2020
For more info: www.bgandg.com/glng

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) certain employees, including Hygo's CEO, had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its IPO would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Garrett Motion Inc. (NYSE:GTX)
Class Period: October 1, 2018 - September 18, 2020
Deadline: November 24, 2020
For more info: www.bgandg.com/gtx

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) due to its agreement to indemnify and reimburse Honeywell for certain asbestos-related liability, Garrett was saddled with an unsustainable level of debt; (2) as a result, Garrett had a highly leveraged capital structure that posed significant challenges to its overall strategic and financial flexibility; (3) as a result of the foregoing, Garrett's ability to gain or hold market share was impaired; (4) as a result of the foregoing, the Company was reasonably likely to seek bankruptcy protection; and (5) consequently, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period: February 28, 2020 - August 18, 2020
Deadline: November 24, 2020
For more info: www.bgandg.com/bmrn

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would not approve the Biologics License Application ("BLA") for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/610939/GLNG-GTX-BMRN-Reminders-Bronstein-Gewirtz-Grossman-LLC-Reminds-Investors-of-Class-Actions-and-Upcoming-Lead-Plaintiff-Deadlines